Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ponderomotive forces in the system of two nanoparticles.
Lozovski V, Lysenko V, Rusinchuk N. Lozovski V, et al. Among authors: lysenko v. Sci Rep. 2022 Oct 22;12(1):17768. doi: 10.1038/s41598-022-22510-8. Sci Rep. 2022. PMID: 36273080 Free PMC article.
Anti-inflammatory and antioxidant effect of cerium dioxide nanoparticles immobilized on the surface of silica nanoparticles in rat experimental pneumonia.
Serebrovska Z, Swanson RJ, Portnichenko V, Shysh A, Pavlovich S, Tumanovska L, Dorovskych A, Lysenko V, Tertykh V, Bolbukh Y, Dosenko V. Serebrovska Z, et al. Among authors: lysenko v. Biomed Pharmacother. 2017 Aug;92:69-77. doi: 10.1016/j.biopha.2017.05.064. Epub 2017 May 19. Biomed Pharmacother. 2017. PMID: 28531802
Enhancing radioprotection: A chitosan-based chelating polymer is a versatile radioprotective agent for prophylactic and therapeutic interventions against radionuclide contamination.
Durand A, Borisova T, Lux F, Howard JA, Tillement A, Kuznietsova H, Dziubenko N, Lysenko V, David L, Morel D, Berbeco R, Komisarenko S, Tillement O, Deutsch E. Durand A, et al. Among authors: lysenko v. PLoS One. 2024 Apr 3;19(4):e0292414. doi: 10.1371/journal.pone.0292414. eCollection 2024. PLoS One. 2024. PMID: 38568898 Free PMC article.
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, Pellegrino C, Klemm N, Russkamp N, Myburgh R, Volta L, Theocharides AP, Kurppa KJ, Ebert BL, Schroeder T, Manz MG, Boettcher S. Mueller J, et al. Among authors: lysenko v. EMBO Mol Med. 2024 Mar;16(3):445-474. doi: 10.1038/s44321-024-00024-2. Epub 2024 Feb 14. EMBO Mol Med. 2024. PMID: 38355749 Free PMC article.
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.
Wildschut MHE, Mena J, Dördelmann C, van Oostrum M, Hale BD, Settelmeier J, Festl Y, Lysenko V, Schürch PM, Ring A, Severin Y, Bader MS, Pedrioli PGA, Goetze S, van Drogen A, Balabanov S, Skoda RC, Lopes M, Wollscheid B, Theocharides APA, Snijder B. Wildschut MHE, et al. Among authors: lysenko v. Nat Commun. 2023 Oct 12;14(1):6414. doi: 10.1038/s41467-023-42101-z. Nat Commun. 2023. PMID: 37828014 Free PMC article.
162 results